Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry

Edward Vincent Loftus, Jr, Walter Reinisch, Remo Panaccione, Sofie Berg, Gabriela Alperovich, Mareike Bereswill, Jasmina Kalabic, Joel Petersson, Roopal Thakkar, Anne M. Robinson, Geert D'Haens

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice. METHODS: Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience were enrolled in the registry and followed for up to 6 years. Effectiveness measurements included the Physician's Global Assessment (PGA, a composite of Harvey Bradshaw Index [HBI] and rectal bleeding score), clinical remission (HBI < 5), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and Work Productivity and Activity Impairment (WPAI) questionnaire. Data were reported for adalimumab-naïve patients and analyzed by baseline immunomodulator use and disease duration. RESULTS: This study evaluated 2057 adalimumab-naïve patients. Mean PGA improved from 7.5 (baseline) to 3.9 (year 1) and 3.3 (year 6). The proportion of patients in HBI remission increased from 29% (573 of 1969; baseline) to 68% (900 of 1331; year 1) and 75% (625 of 831; year 6). Patients stratified by baseline immunomodulator use had similar HBI remission rates; patients with disease duration <2 years achieved numerically higher HBI remission rates than patients with longer disease duration. Patient-reported SIBDQ and WPAI scores improved at year 1; all WPAI subscore improvements were clinically meaningful (≥7% point change) at year 1 and maintained through year 6. Serious infections were reported in 11.1% of patients; incidence rates of malignancies, lymphoma, and demyelinating disorders were low. CONCLUSION: Adalimumab therapy, as used in routine clinical practice, improved physician-reported and patient-reported disease outcomes and remission rates for up to 6 years. No new safety signals were observed.

Original languageEnglish (US)
Pages (from-to)1522-1531
Number of pages10
JournalInflammatory bowel diseases
Volume25
Issue number9
DOIs
StatePublished - Aug 20 2019

Fingerprint

Crohn Disease
Registries
Prostaglandins A
Immunologic Factors
Physicians
Safety
Adalimumab
Demyelinating Diseases
Inflammatory Bowel Diseases
Lymphoma
Hemorrhage
Incidence
Infection
Surveys and Questionnaires

Keywords

  • clinical practice
  • disease activity
  • long-term effectiveness
  • long-term safety
  • work productivity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease : Results of the PYRAMID Registry. / Loftus, Jr, Edward Vincent; Reinisch, Walter; Panaccione, Remo; Berg, Sofie; Alperovich, Gabriela; Bereswill, Mareike; Kalabic, Jasmina; Petersson, Joel; Thakkar, Roopal; Robinson, Anne M.; D'Haens, Geert.

In: Inflammatory bowel diseases, Vol. 25, No. 9, 20.08.2019, p. 1522-1531.

Research output: Contribution to journalArticle

Loftus, Jr, EV, Reinisch, W, Panaccione, R, Berg, S, Alperovich, G, Bereswill, M, Kalabic, J, Petersson, J, Thakkar, R, Robinson, AM & D'Haens, G 2019, 'Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry', Inflammatory bowel diseases, vol. 25, no. 9, pp. 1522-1531. https://doi.org/10.1093/ibd/izz008
Loftus, Jr, Edward Vincent ; Reinisch, Walter ; Panaccione, Remo ; Berg, Sofie ; Alperovich, Gabriela ; Bereswill, Mareike ; Kalabic, Jasmina ; Petersson, Joel ; Thakkar, Roopal ; Robinson, Anne M. ; D'Haens, Geert. / Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease : Results of the PYRAMID Registry. In: Inflammatory bowel diseases. 2019 ; Vol. 25, No. 9. pp. 1522-1531.
@article{dcaac26c783b4feba3459fdc8facb998,
title = "Adalimumab Effectiveness Up to Six Years in Adalimumab-na{\"i}ve Patients with Crohn's Disease: Results of the PYRAMID Registry",
abstract = "BACKGROUND: PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice. METHODS: Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience were enrolled in the registry and followed for up to 6 years. Effectiveness measurements included the Physician's Global Assessment (PGA, a composite of Harvey Bradshaw Index [HBI] and rectal bleeding score), clinical remission (HBI < 5), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and Work Productivity and Activity Impairment (WPAI) questionnaire. Data were reported for adalimumab-na{\"i}ve patients and analyzed by baseline immunomodulator use and disease duration. RESULTS: This study evaluated 2057 adalimumab-na{\"i}ve patients. Mean PGA improved from 7.5 (baseline) to 3.9 (year 1) and 3.3 (year 6). The proportion of patients in HBI remission increased from 29{\%} (573 of 1969; baseline) to 68{\%} (900 of 1331; year 1) and 75{\%} (625 of 831; year 6). Patients stratified by baseline immunomodulator use had similar HBI remission rates; patients with disease duration <2 years achieved numerically higher HBI remission rates than patients with longer disease duration. Patient-reported SIBDQ and WPAI scores improved at year 1; all WPAI subscore improvements were clinically meaningful (≥7{\%} point change) at year 1 and maintained through year 6. Serious infections were reported in 11.1{\%} of patients; incidence rates of malignancies, lymphoma, and demyelinating disorders were low. CONCLUSION: Adalimumab therapy, as used in routine clinical practice, improved physician-reported and patient-reported disease outcomes and remission rates for up to 6 years. No new safety signals were observed.",
keywords = "clinical practice, disease activity, long-term effectiveness, long-term safety, work productivity",
author = "{Loftus, Jr}, {Edward Vincent} and Walter Reinisch and Remo Panaccione and Sofie Berg and Gabriela Alperovich and Mareike Bereswill and Jasmina Kalabic and Joel Petersson and Roopal Thakkar and Robinson, {Anne M.} and Geert D'Haens",
year = "2019",
month = "8",
day = "20",
doi = "10.1093/ibd/izz008",
language = "English (US)",
volume = "25",
pages = "1522--1531",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease

T2 - Results of the PYRAMID Registry

AU - Loftus, Jr, Edward Vincent

AU - Reinisch, Walter

AU - Panaccione, Remo

AU - Berg, Sofie

AU - Alperovich, Gabriela

AU - Bereswill, Mareike

AU - Kalabic, Jasmina

AU - Petersson, Joel

AU - Thakkar, Roopal

AU - Robinson, Anne M.

AU - D'Haens, Geert

PY - 2019/8/20

Y1 - 2019/8/20

N2 - BACKGROUND: PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice. METHODS: Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience were enrolled in the registry and followed for up to 6 years. Effectiveness measurements included the Physician's Global Assessment (PGA, a composite of Harvey Bradshaw Index [HBI] and rectal bleeding score), clinical remission (HBI < 5), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and Work Productivity and Activity Impairment (WPAI) questionnaire. Data were reported for adalimumab-naïve patients and analyzed by baseline immunomodulator use and disease duration. RESULTS: This study evaluated 2057 adalimumab-naïve patients. Mean PGA improved from 7.5 (baseline) to 3.9 (year 1) and 3.3 (year 6). The proportion of patients in HBI remission increased from 29% (573 of 1969; baseline) to 68% (900 of 1331; year 1) and 75% (625 of 831; year 6). Patients stratified by baseline immunomodulator use had similar HBI remission rates; patients with disease duration <2 years achieved numerically higher HBI remission rates than patients with longer disease duration. Patient-reported SIBDQ and WPAI scores improved at year 1; all WPAI subscore improvements were clinically meaningful (≥7% point change) at year 1 and maintained through year 6. Serious infections were reported in 11.1% of patients; incidence rates of malignancies, lymphoma, and demyelinating disorders were low. CONCLUSION: Adalimumab therapy, as used in routine clinical practice, improved physician-reported and patient-reported disease outcomes and remission rates for up to 6 years. No new safety signals were observed.

AB - BACKGROUND: PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice. METHODS: Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience were enrolled in the registry and followed for up to 6 years. Effectiveness measurements included the Physician's Global Assessment (PGA, a composite of Harvey Bradshaw Index [HBI] and rectal bleeding score), clinical remission (HBI < 5), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and Work Productivity and Activity Impairment (WPAI) questionnaire. Data were reported for adalimumab-naïve patients and analyzed by baseline immunomodulator use and disease duration. RESULTS: This study evaluated 2057 adalimumab-naïve patients. Mean PGA improved from 7.5 (baseline) to 3.9 (year 1) and 3.3 (year 6). The proportion of patients in HBI remission increased from 29% (573 of 1969; baseline) to 68% (900 of 1331; year 1) and 75% (625 of 831; year 6). Patients stratified by baseline immunomodulator use had similar HBI remission rates; patients with disease duration <2 years achieved numerically higher HBI remission rates than patients with longer disease duration. Patient-reported SIBDQ and WPAI scores improved at year 1; all WPAI subscore improvements were clinically meaningful (≥7% point change) at year 1 and maintained through year 6. Serious infections were reported in 11.1% of patients; incidence rates of malignancies, lymphoma, and demyelinating disorders were low. CONCLUSION: Adalimumab therapy, as used in routine clinical practice, improved physician-reported and patient-reported disease outcomes and remission rates for up to 6 years. No new safety signals were observed.

KW - clinical practice

KW - disease activity

KW - long-term effectiveness

KW - long-term safety

KW - work productivity

UR - http://www.scopus.com/inward/record.url?scp=85071422457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071422457&partnerID=8YFLogxK

U2 - 10.1093/ibd/izz008

DO - 10.1093/ibd/izz008

M3 - Article

C2 - 30753510

AN - SCOPUS:85071422457

VL - 25

SP - 1522

EP - 1531

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 9

ER -